Alcohol Consumption and Risk of Parkinson's Disease: Data From a Large Prospective European Cohort.


Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
07 2020
Historique:
received: 12 09 2019
revised: 30 01 2020
accepted: 03 03 2020
pubmed: 2 5 2020
medline: 28 4 2021
entrez: 2 5 2020
Statut: ppublish

Résumé

Parkinson's disease (PD) etiology is not well understood. Reported inverse associations with smoking and coffee consumption prompted the investigation of alcohol consumption as a risk factor, for which evidence is inconclusive. To assess the associations between alcohol consumption and PD risk. Within NeuroEPIC4PD, a prospective European population-based cohort, 694 incident PD cases were ascertained from 209,998 PD-free participants. Average alcohol consumption at different time points was self-reported at recruitment. Cox regression hazard ratios were estimated for alcohol consumption and PD occurrence. No associations between baseline or lifetime total alcohol consumption and PD risk were observed. Men with moderate lifetime consumption (5-29.9 g/day) were at ~50% higher risk compared with light consumption (0.1-4.9 g/day), but no linear exposure-response trend was observed. Analyses by beverage type also revealed no associations with PD. Our data reinforce previous findings from prospective studies showing no association between alcohol consumption and PD risk. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Sections du résumé

BACKGROUND
Parkinson's disease (PD) etiology is not well understood. Reported inverse associations with smoking and coffee consumption prompted the investigation of alcohol consumption as a risk factor, for which evidence is inconclusive.
OBJECTIVE
To assess the associations between alcohol consumption and PD risk.
METHODS
Within NeuroEPIC4PD, a prospective European population-based cohort, 694 incident PD cases were ascertained from 209,998 PD-free participants. Average alcohol consumption at different time points was self-reported at recruitment. Cox regression hazard ratios were estimated for alcohol consumption and PD occurrence.
RESULTS
No associations between baseline or lifetime total alcohol consumption and PD risk were observed. Men with moderate lifetime consumption (5-29.9 g/day) were at ~50% higher risk compared with light consumption (0.1-4.9 g/day), but no linear exposure-response trend was observed. Analyses by beverage type also revealed no associations with PD.
CONCLUSION
Our data reinforce previous findings from prospective studies showing no association between alcohol consumption and PD risk. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Identifiants

pubmed: 32357270
doi: 10.1002/mds.28039
pmc: PMC7496254
doi:

Substances chimiques

Coffee 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1258-1263

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 570/A16491
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0500300
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC-UU_12015/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205212/Z/16/Z
Pays : United Kingdom
Organisme : British Heart Foundation
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C864/A14136
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Références

Int J Cancer. 2018 Aug 15;143(4):801-812
pubmed: 29524225
Eur J Clin Nutr. 2011 Oct;65(10):1079-87
pubmed: 21559044
PLoS One. 2013 Jun 19;8(6):e66452
pubmed: 23840473
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Int J Cancer. 2015 Oct 15;137(8):1921-30
pubmed: 25677034
J Alzheimers Dis. 2010;20 Suppl 1:S221-38
pubmed: 20182023
Ann Neurol. 2002 Sep;52(3):276-84
pubmed: 12205639
Arch Gerontol Geriatr. 2015 Nov-Dec;61(3):510-6
pubmed: 26272284
Int J Epidemiol. 2019 Jun 1;48(3):912-925
pubmed: 30462234
Mov Disord. 2012 Jul;27(8):980-7
pubmed: 22714720
Lancet Neurol. 2006 Jun;5(6):525-35
pubmed: 16713924
Neurodegener Dis. 2015;15(6):331-8
pubmed: 26375921
J Neurol. 2019 Aug;266(8):1821-1834
pubmed: 30155737
Mov Disord. 2014 May;29(6):819-22
pubmed: 24590499
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Ann Neurol. 2003 Aug;54(2):170-5
pubmed: 12891669
BMJ. 2018 May 29;361:k934
pubmed: 29844013
Horm Behav. 2013 Feb;63(2):308-14
pubmed: 22687345

Auteurs

Susan Peters (S)

Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands.

Valentina Gallo (V)

Centre for Primary Care and Public Health, Queen Mary University of London, London, UK.

Paolo Vineis (P)

School of Public Health, Imperial College London, London, UK.

Lefkos T Middleton (LT)

School of Public Health, Imperial College London, London, UK.

Lars Forsgren (L)

Department of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.

Carlotta Sacerdote (C)

Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, Turin, Italy.
Center for Cancer Prevention, Turin, Italy.

Sabina Sieri (S)

Epidemiology and Prevention Unit, Fondazione Istitutodi Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.

Andreas Kyrozis (A)

Hellenic Health Foundation, Athens, Greece.
First Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece.

María-Dolores Chirlaque (MD)

Department of Epidemiology, Regional Health Council, Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia, Spain.
Centrode Investigación Biomédica en Red (CIBER) in Epidemiology and Public Health, Madrid, Spain.
Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain.

Raul Zamora-Ros (R)

Unit of Nutrition and Cancer, Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Barcelona, Spain.

Oskar Hansson (O)

Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Memory Clinic, Skåne University Hospital, Lund, Sweden.

Jesper Petersson (J)

Department of Neurology, Skåne University Hospital, Lund University, Malmö, Sweden.

Verena Katzke (V)

German Cancer Research Centre, Heidelberg, Germany.

Tilman Kühn (T)

German Cancer Research Centre, Heidelberg, Germany.

Olatz Mokoroa (O)

Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain.

Giovanna Masala (G)

Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network-Cancer Research and Prevention Institute (ISPRO), Florence, Italy.

Eva Ardanaz (E)

Centrode Investigación Biomédica en Red (CIBER) in Epidemiology and Public Health, Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
Institutode Investigación Sanitaria de Navarra (IdiSNA), Navarra Institute for Health Research, Pamplona, Spain.

Salvatore Panico (S)

Dipartimento di Medicina Clinica e Chirurgia, Federico II University Naples, Naples, Italy.

Manuela M Bergmann (MM)

German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany.

Timothy J Key (TJ)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Elisabete Weiderpass (E)

International Agency for Research on Cancer, Lyon, France.

Pietro Ferrari (P)

International Agency for Research on Cancer, Lyon, France.

Roel Vermeulen (R)

Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
School of Public Health, Imperial College London, London, UK.
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH